Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study

Blood (2025) 146 (Supplement 1): 920.

https://doi.org/10.1182/blood-2025-920

Published: 2025

Journal Articles

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Blood (2025) 146 (Supplement 1): 6079.

https://doi.org/10.1182/blood-2025-6079

Published: 2025

Journal Articles

Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study

Blood (2025) 146 (Supplement 1): 2263.

https://doi.org/10.1182/blood-2025-2263

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial

Blood (2025) 146 (Supplement 1): 911.

https://doi.org/10.1182/blood-2025-911

Published: 2025

Journal Articles

Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort

Blood (2025) 146 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2025-1978

Published: 2025

Journal Articles

Post-remission immunotherapy with vididencel for a measurable residual disease defined high-risk sub-group of adult patients with Acute Myeloid Leukemia in first complete hematological remission: Updated results of the european advance II study demonstrate robust safety, relapse-free and overall survival benefit.

Arjan Van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Janine Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Alex Karlsson-Parra, Tariq Mughal, Bjorn Gjertsen

Blood (2025) 146 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2025-1647

Published: 2025

Journal Articles

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

Blood (2025) 146 (Supplement 1): 6011.

https://doi.org/10.1182/blood-2025-6011

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Veit L. Buecklein, Francis A. Ayuk, Tobias A.W. Holderried, Christine Mai, Bradley Kievit, Rob Blisset, Brett Doble, Geoff Reid, Laura Reimeir, Caroline Bruns, Sachin Vadgama

Blood (2024) 144 (Supplement 1): 5037.

https://doi.org/10.1182/blood-2024-205589

Published: 2024

Journal Articles

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Blood (2024) 144 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2024-203487

Published: 2024

Journal Articles

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Blood (2024) 144 (Supplement 1): 769.

https://doi.org/10.1182/blood-2024-193308

Published: 2024

Journal Articles

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Arjan A. van de Loosdrecht, Eva-Maria Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jacqueline Cloos, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2024) 144 (Supplement 1): 2875.

https://doi.org/10.1182/blood-2024-201374

Published: 2024

Journal Articles

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Blood (2024) 144 (Supplement 1): 364.

https://doi.org/10.1182/blood-2024-194768

Published: 2024

Journal Articles

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Blood (2024) 144 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2024-204824

Published: 2024

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

Sequential Dosing of Next-Generation IMA203CD8 TCR-T-Cell Therapy Targeting PRAME in Combination with BRAF-/MEK-Inhibition in a Melanoma Patient with Progressive Disease - a Case Report

Friederike Schmitz, Martin Schumacher, Annkristin Heine, Annette Busch, Mario Heine, Julian A. Luetkens, Jennifer Landsberg, Niklas Schäfer, Oliver Ebert, Robert Zeiser, John G. Gribben, Peter Brossart, Tobias A.W. Holderried

Blood (2024) 144 (Supplement 1): 7194.

https://doi.org/10.1182/blood-2024-194461

Published: 2024

Journal Articles

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Arjan A. van de Loosdrecht, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Hester Van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2023) 142 (Supplement 1): 769.

https://doi.org/10.1182/blood-2023-185532

Published: 2023

Journal Articles

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Hester Van Zeeburg, Eva Wagner Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina Van Elssen, Aristoteles Giagounidis, Soren Lehmann, Jeroen Rovers, Bjorn T. Gjertsen, Arjan A. van de Loosdrecht

Blood (2023) 142 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2023-188573

Published: 2023

Journal Articles

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Arjan A. Van de Loosdrecht, Jacqueline Cloos, Eva-Maria Wagner-Drouet, Uwe Platzbecker, Tobias A.W. Holderried, Catharina van Elssen, Aristoteles Giagounidis, Sören Lehmann, Hester J.T. van Zeeburg, Jeroen Rovers, Bjorn T. Gjertsen

Blood (2022) 140 (Supplement 1): 1714–1715.

https://doi.org/10.1182/blood-2022-162169

Published: 2022

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study

Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party

Health-related quality of life (HRQoL) in patients with newly diagnosed multiple myeloma (NDMM) eligible for transplantation and treated with isatuximab, lenalidomide, bortezomib, and dexamethasone (Isa-RVd) versus rvd alone: Results from part 1 of the GMMG-HD7 study

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial

Long-term outcome and risk factors for relapse after allogeneic hematopoietic stem cell transplantation in myelofibrosis: Results from a large multicenter cohort

Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic gvhd treatment: Multicenter retrospective analysis of a large german-austrian cohort of the belumosudil managed-access program.

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

Active Immunotherapy with Vididencel As Maintenance Treatment in MRD+ AML Patients in CR1 Results in Strong Anti-Tumor Immune Responses and Durable Long-Term Survival in Patients with an Immune Competent Immune Profile

Impact of Minimal Residual Disease on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Treated with Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy in the Phase 3 GMMG-HD7 Trial

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Sequential Dosing of Next-Generation IMA203CD8 TCR-T-Cell Therapy Targeting PRAME in Combination with BRAF-/MEK-Inhibition in a Melanoma Patient with Progressive Disease - a Case Report

Induction of Cellular and Humoral Immune Responses Is Associated with Durable Remissions in MRD+ AML-Patients after Maintenance Treatment with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Vaccination Using an Allogeneic Leukemia-Derived Dendritic Cell Vaccine, Maintains and Improves Frequencies of Circulating Antigen Presenting Dendritic Cells Correlating with Relapse Free and Overall Survival in AML Patients

Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only